Jonathan Rubino

Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

N. André, X. Paoletti, B. Geoerger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.

N. André, X. Paoletti, B. Geoerger, 2021, European journal of cancer.

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.

N. André, X. Paoletti, B. Geoerger, 2021, European journal of cancer.

Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART.

A. Marchais, S. Gatz, K. Nysom, 2024, European journal of cancer.